Canaccord Genuity Reiterates Buy Rating on AngioDynamics (ANGO)

Canaccord Genuity analyst William Plovanic reiterated a Buy rating and $18.00 price target on AngioDynamics (NASDAQ: ANGO).

The analyst commented: "CMS published its 2026 Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems final rule. As proposed, CMS kept ANGO’s new CPT I code for prostate ablation (55877) mapped to APC 5362, which reimburses $10,860.07 under OPPS. With the reimbursement reaffirmed, and level I CPT codes going into effect January 1, 2026, we believe that ANGO has the opportunity to capitalize on the recent prostate momentum and reduce the hurdles for patient access related to reimbursement. The level I codes also give the company physician reimbursement under PFS, as well as reduce the instances of automatic denials from commercial payors. We expect that ANGO will be able to benefit from these reimbursement enhancements over the course of CY2026. We reiterate our BUY rating on shares of ANGO."

For an analyst ratings summary and ratings history on AngioDynamics click here. For more ratings news on AngioDynamics click here.

Shares of AngioDynamics closed at $12.30 yesterday.

You May Also Be Interested In

• Jefferies Upgrades U.S. Bancorp (USB) to Buy
• Stifel Canada Starts Apotex Health Corp (APTX:CN) at Buy
• Morgan Stanley Downgrades Truist Financial (TFC) to Equalweight